Genmab — April 2024

[gentogen]

9 of 10 Kesimpta patients free of disease activity (NEDA-3) at year 6 in both continuous and switch groups

[gentogen]

Fra Novartis (tidligere link)

[transalp]

Go morgen..

[Helge_LarsenPI-redaktør]

Godmorgen

[bibob]

God morgen.

[Stroka]

God morgen

[LP90]

Godmorgen

[E_L]

Roche Ocrevus sales Q1 '24 CHF 1.658bn = +8% over Q1 '23

[E_L]

Ocrevus Q1 '23 was 1.636 and Q4 '23 was 1.614

[w]

kesimpta Q4
'23?

[Bulder]

641 mio $

[w]

tjek, tak

[Sukkeralf]

+8% seems wrong according to the numbers you mention

[E_L]

ok, i see. this is from today https://www.roche.com/investors/updates/inv-update-2024-04-24 and this from february https://assets.roche.com/f/176343/x/5a5b5d48d1/240201_ir_fy23_en.pdf

[E_L]

without looking into it i wonder if it could have anything to do with them reporting on the basis of constant exchange rate sales growth

[Solsen]

In number of pts treated it could perhaps be 0% for Ocrevus. I’ll try to find that later.

[Solsen]

We could very well se Kesimpta take market share from Ocrevus I belive.

[E_L]

ASCO Abstract title #

2533 Acasunlimab (DuoBody-PD-L1x4-1BB) alone or in combination with pembrolizumab (pembro) in patients (pts) with previously treated metastatic non-small cell lung cancer (mNSCLC): Initial results of a randomized, open-label, phase 2 trial. https://meetings.asco.org/abstracts-presentations/233961

[E_L]

ASCO Abstract title #6012 Tisotumab vedotin in head and neck squamous cell carcinoma: Updated analysis from innovaTV 207 Part C. https://meetings.asco.org/abstracts-presentations/234881

[E_L]

ASCO Abstract title #5531 Tisotumab vedotin in 2L/3L recurrent or metastatic cervical cancer: Subsequent therapy data from ENGOT-cx12/GOG-3057/innovaTV 301. https://meetings.asco.org/abstracts-presentations/234587